IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies

INconnect28 - 29 September 2017, Berlin, Germany.
Due to evolving technology and accelerated growth in research and development activities, cloud computing and IT business technology have increased rapidly. Over the past decades, cloud computing has had profound impact in Life Sciences industry by bringing efficiencies, allowing enterprise-wide agility, and boosting patient outcomes. Cloud computing solutions has reshaped promotional strategies of various Life Science companies and transformed modes of interactions with physicians.

As Life Science sector is currently improving and accelerating its correlation with IT, the Life Sciences Cloud Coalition have moved to the cloud computing and working with their patient through it.

Global Cloud Computing in Life Science Market is expected to expand at a rapid pace during the period of 2015 - 2023 due to the increasing use of cloud computing in Life Science research and development.

This event will serve as a business networking platform as well as a scientific examination of the advantages and disadvantages in implementing IT modernization and cloud computing.

Key Topics

  • Examination of the EU General Data Protection Regulation and practical implementation
  • Analysis of Data security and Privacy Global Outlook
  • Benchmark your IT approach to transformation
  • Understanding the need for Scalability and Flexibility of Cloud Computing
  • IT Infrastructure Modernisation in Pharma and Rea
  • World Implementations
  • Factors driving Digital and Mobile Technologies in Patient Engagement
  • Cloudy 2020: Cloudy Opportunities and Challenges in the future
  • Harmonization of data privacy laws across Europe
  • Discussion of pros and cons of private cloud and public cloud
  • e-commerce trends and application in Cloud

Target Audience

  • Pharmaceutical companies
  • Cloud Content Solution/Software Providers
  • Biotechnology companies
  • Medical Technology companies
  • Research Centers
  • Physicians

For further information, please visit:
http://www.inconnect.net/events/events/it-transformation-and-cloud-content-management-for-medtech-biotechnology-and-pharmaceutical-companies

About INconnect
Academic management research shows that knowledge is a crucial asset for companies concerning sustained competitive advantage. Markets provide opportunities for companies to succeed in organizing themselves around new information on industry trends and technology. Those are the companies that can and will innovate.

Improved technologies and strategies are required for innovation. The only possible fuel for innovation are ideas. Ideas arise when the right people, get the right information, in the right context.

INconnect uses its extensive international network in top-executive event management to bring together industry leaders, lawmakers and experts.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]